Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancerAmanda E.D. Van Swearingen, Carey K. Anders, Marni B. Siegel et al.|Neuro-Oncology|2017Cited by 42